XML 28 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Details Textual) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Cash Equivalents, at Carrying Value $ 1,900,000 $ 2,700,000
Allocated Share-based Compensation Expense 979,151 127,488
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award the Company modified the vesting terms for its unvested performance based stock options and unvested restricted common stock of fifteen employees and non-employee directorsto vest on the earlier of the first closing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015.  
Share-based Compensation, Total 979,151 127,488
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 354,027  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total 1,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 2.92  
Undistributed Earnings Allocated to Participating Securities 85,209  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 10 months 28 days  
Restricted Stock Award [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 0  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0  
Performance Shares [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 907,336  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price, Beginning Balance $ 2.81  
Allocated Share-based Compensation Expense $ 422,000  
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award the Company modified 907,336 existing time-vested and performance stock options by lowering the exercise price to $2.81. Additionally, the Company modified the vesting terms for its unvested performance stock options and unvested restricted stock to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015  
Restricted Stock [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12,000  
Restricted Stock Units (RSUs) [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 15,000  
License and Milestone Revenues [Member]
   
Percentage Of Revenue Accounted By Single Customer   100.00%
Research Revenue [Member]
   
Percentage Of Revenue Accounted By Single Customer   100.00%